Scientists launch new attack against AIDS

EU-funded researchers have developed a new defence against infection from the AIDS (acquired immune deficiency syndrome) virus. The pioneering method involves creating a protective shield that restricts the virus from making contact with a susceptible host cell and penetrating the immune system. Published in the journal Chemistry & Biology, the results pave the way for future pharmaceutical drugs that could combat the disease in its early stages.

The three-year breakthrough study was led by Dr Félix Goñi of the Consejo Superior de Investigaciones Científicas (CSIC) in Spain, together with several CSIC departments and Spanish institutes specialising in chemistry and molecular biology.

Their novel approach is based on the regulation of cell membrane fluidity in order to prevent the occurrence of 'membrane fusion', where contact is established between the cell membranes and the membrane of the AIDS virus.

As the protective, fragile layer of the cytoplasm, the membrane of a cell has a similar structure to that of the AIDS virus membrane. Fusion occurs when both membranes make contact, thus producing an orifice that acts as an entry point for the virus. At this stage, the virus attaches to a cell receptor and begins to spread.

The objective for Dr Goñi and his team was to make the membrane structure stronger and more rigid so as to prevent fusion from taking place altogether, and to avoid the subsequent viral escalation.

Dr Goñi explained that in order for the orifice to be created, the membranes must be fluid and mobile. To counter this, the team discovered a procedure that makes the cell membranes tougher and less yielding.

"This [method] could well give rise to a new pharmaceutical drug, which makes the membranes more rigid and impede the entrance of the AIDS virus. Instead of the membrane being flexible, a kind of armour is established which makes the cell impenetrable," Dr Goñi pointed out.

Almost all existing methods to treat the AIDS virus focus on the need to stop the spread of the virus when it is already inside the first cell. An exception is Enfurvitide, a treatment that aims to stop the virus from entering the host cell but is based on a completely different principle to the one developed by Dr Goñi and his team.

Beyond the AIDS virus, the strategy also has the potential to be applied to the flu virus and other viruses with membrane.

The research was supported by two EU projects totalling EUR 21.89 million: CHAIN (Collaborative HIV and anti-HIV drug resistance network), and INNOCHEM (Innovative chemokine-based therapeutic strategies for autoimmunity and chronic inflammation). These projects were funded under the Health Theme of the Seventh Framework Programme (FP7) and the 'Life sciences, genomics and biotechnology for health' Thematic Area of the Sixth Framework Programme (FP6) respectively.

For more information, please visit:

Copyright ©European Communities, 2010
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Pfizer and Lilly announce top-line results from lo…

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the stu...

Bristol-Myers Squibb reports first quarter financi…

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2019 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (a...

Walnuts may help lower blood pressure for those at…

When combined with a diet low in saturated fats, eating walnuts may help lower blood pressure in people at risk for cardiovascular disease, according to a new Penn State ...

Amgen ignites a social fitness movement to support…

Amgen (NASDAQ:AMGN) launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support t...

Comprehensive tumor profiling promises new therape…

The WINTHER trial, NCT01856296, led by investigators from Vall d'Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave...

AstraZeneca starts artificial intelligence collabo…

AstraZeneca and BenevolentAI today began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treat...

Possible link between autism and antidepressants u…

An international team led by Duke-NUS Medical School has found a potential link between autistic-like behaviour in adult mice and exposure to a common antidepressant in t...

Chemotherapy or not?

Case Western Reserve University researchers and partners, including a collaborator at Cleveland Clinic, are pushing the boundaries of how "smart" diagnostic-imaging machi...

Researchers define Alzheimer's-like brain disorder

A brain disorder that mimics symptoms of Alzheimer's disease has been defined with recommended diagnostic criteria and guidelines for advancing future research on the con...

Drugs to prevent stroke and dementia show promise …

Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small study...

Amgen and Syapse enter precision medicine collabor…

Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, announced a precisio...

Personalizing precision medicine with combination …

Precision oncology often relies on treating patients with a single, molecularly matched therapy that targets one mutation in their tumor. In a report, published online in...